Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy

Authors Neill MG, Shahani R, Zlotta AR

Published 8 February 2008 Volume 2008:4(1) Pages 11—18


Mischel G Neill, Rohan Shahani, Alexandre R Zlotta

Division of Urology, Department of Surgical Oncology, Princess Margaret and Mount Sinai Hospitals, University of Toronto, Toronto, Canada

Abstract: The efficacy of tamsulosin at the cost of a relatively benign side effect profile has been attributed to receptor selectivity directed at the α1a and α1d adrenergic receptor subtypes. The oral-controlled absorption system (OCAS®) represents a drug delivery refinement that incorporates a matrix of gel-forming and gel-enhancing agents to promote a constant drug release independent of environmental food or fluid. There are clinical data to support the concept that drug peaks are lessened and that drug release continues throughout the alimentary tract due to the OCAS formulation. Furthermore this equates with less adverse effects on physiologic parameters. To date however improvements in cardiovascular symptoms such as dizziness, headache and syncope have not been demonstrated in healthy men. Ejaculatory dysfunction appears less problematic with the OCAS preparation. Tamsulosin OCAS may be of greatest benefit to men with cardiovascular co-morbidities taking anti-hypertensive medications that might predispose them to symptomatic hypotensive episodes. It will be necessary to evaluate this group of men more closely in further trials to determine what they stand to gain from changing medications, and then relate this to drug costs to draw a final conclusion as to the place of tamsulosin OCAS in contemporary urological practice.

Keywords: lower urinary tract symptoms, benign prostatic hyperplasia, tamsulosin OCAS, safety, efficacy, tolerability

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Physiologically based pharmacokinetic modeling of zinc oxide nanoparticles and zinc nitrate in mice

Chen WY, Cheng YH, Hsieh NH, Wu BC, Chou WC, Ho CC, Chen JK, Liao CM, Lin P

International Journal of Nanomedicine 2015, 10:6277-6292

Published Date: 5 October 2015

Pathogens in COPD exacerbations identified by comprehensive real-time PCR plus older methods

Shimizu K, Yoshii Y, Morozumi M, Chiba N, Ubukata K, Uruga H, Hanada S, Saito N, Kadota T, Ito S, Wakui H, Takasaka N, Minagawa S, Kojima J, Hara H, Numata T, Kawaishi M, Saito K, Araya J, Kaneko Y, Nakayama K, Kishi K, Kuwano K

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2009-2016

Published Date: 23 September 2015

Simultaneous growth of two cancer cell lines demonstrates variability in growth rates

Hamon A, Tosolini M, Ycart B, Pont F, Fournie JJ

Open Access Medical Statistics 2014, 4:29-37

Published Date: 28 November 2014

Contraceptive implants: current perspectives

Rowlands S, Searle S

Open Access Journal of Contraception 2014, 5:73-84

Published Date: 23 September 2014

Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women

Prasad M, Reriani M, Khosla S, Gössl M, Lennon R, Gulati R, Prasad A, Lerman LO, Lerman A

Vascular Health and Risk Management 2014, 10:533-538

Published Date: 26 August 2014


Sørensen HT, Friborg S, Rungby J, Christiansen JS, Vaag A, Beck-Nielsen H

Clinical Epidemiology 2012, 4:49-50

Published Date: 20 December 2012

Type I interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma

Tomiyama Y, Yoshioka N, Yanai Y, Kawase T, Nishina S, Hara Y, Yoshida K, Korenaga K, Korenaga M, Hino K

Hepatic Medicine: Evidence and Research 2011, 3:45-52

Published Date: 26 April 2011

Non-invasive ventilation in exacerbations of COPD

Nicolino Ambrosino, Guido Vagheggini

International Journal of Chronic Obstructive Pulmonary Disease 2007, 2:471-476

Published Date: 15 January 2008